world
Roche Reports Declining Sales for First Quarter of 2026 Amid Competition and Currency Pressures
Swiss pharmaceutical company Roche announced declining sales for the first quarter of 2026. The downturn was attributed to increased competition for its older medicines and the appreciation of the Swiss franc against the dollar. The report highlights ongoing challenges in the pharmaceutical sector.
swissinfo.chAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Swiss pharmaceutical giant Roche reported declining sales for the first quarter of 2026, impacted by competitive pressures and currency fluctuations. @business reported that Roche's first-quarter 2026 sales were hurt by competition for its older medicines, which faced increased rivalry in key markets.
The sales decline was further exacerbated by the Swiss franc’s appreciation against the dollar, adding financial strain to the company's performance during the period.
Transparency
1 source · single source
CorroborationLimited · 1 source
